Bepranemab

DB17945InvestigationalProtein Based Therapies

Bepranemab is a recombinant humanized Igg4P monoclonal antibody directed against human Tau.

Mechanism
Curator reviewed
Also known as
Immunoglobulin g4 (226-proline), anti-(human tau protein) (human-rattus norvegicus monoclonal ucb0107 .gamma.4-chain), disulfide with human-rattus norvegicus monoclonal ucb0107 .kappa.-chain, dimer
Code names
UCB-0107

Resolves to

Compound
UNII9M1GV6L389CAS2244960-75-4
Targets
P10636MAPT

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
5Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Bepranemab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In